Thailand To Switch From Chinese To WHO Experts For Vaccine Plant
This article was originally published in PharmAsia News
Thailand's Government Pharmaceutical Organisation is canceling plans to rely on Chinese experts to build a plant in Thailand to produce avian influenza vaccines. The GPO's managing director said it would rely on the World Health Organization to provide the experts it needs. The Thai biotech agency previously had said it would work with the China National Biotech Group to build the plant. But the plan faced difficulties caused by a Japanese patent on the cell-based technology to be used and Chinese authorities were unable to reach a deal with the patent owners. (Click here for more
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.